Try our Advanced Search for more refined results

How A Merck Attorney's Lies Torpedoed A $200M Patent Verdict

By Ryan Davis | June 10, 2016, 6:27 PM EDT

On a conference call of drug company officials in March 2004, Merck & Co. Inc. in-house patent prosecutor Philippe Durette assured representatives of Pharamasset Inc. that he could be trusted with information on its “crown jewel” hepatitis C research. That was the first in a series of lies Durette would tell over the course of the next decade that would end with the reversal this week of a $200 million patent infringement verdict Merck won against Gilead Sciences Inc.

Want to read this article? Try Law360 FREE for seven days

Read the full story now

Already a subscriber? Click here to login